Acute Myeloid Leukemia Stocks List

Recent Signals

Date Stock Signal Type
2021-02-26 AIKI Fell Below 50 DMA Bearish
2021-02-26 AIKI NR7 Range Contraction
2021-02-26 ALXO Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-02-26 ALXO Spinning Top Other
2021-02-26 ALXO Fell Below 20 DMA Bearish
2021-02-26 ALXO 50 DMA Resistance Bearish
2021-02-26 ALXO Calm After Storm Range Contraction
2021-02-26 APRE Stochastic Reached Oversold Weakness
2021-02-26 APTO Lower Bollinger Band Walk Weakness
2021-02-26 APTO New 52 Week Low Weakness
2021-02-26 APTO NR7 Range Contraction
2021-02-26 APTO New 52 Week Closing Low Bearish
2021-02-26 ARAV Spinning Top Other
2021-02-26 ARAV 20 DMA Support Bullish
2021-02-26 ARAV MACD Bearish Signal Line Cross Bearish
2021-02-26 ARAV Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-26 ARAV New Downtrend Bearish
2021-02-26 ARGX Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-26 ATNM New Downtrend Bearish
2021-02-26 ATNM Spinning Top Other
2021-02-26 BEAM Calm After Storm Range Contraction
2021-02-26 BEAM MACD Bearish Centerline Cross Bearish
2021-02-26 BLRX Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-26 CGEM 20 DMA Support Bullish
2021-02-26 CGEM 1,2,3 Pullback Bullish Bullish Swing Setup
2021-02-26 CLLS Lower Bollinger Band Walk Weakness
2021-02-26 CLLS Crossed Above 200 DMA Bullish
2021-02-26 CLLS Doji - Bullish? Reversal
2021-02-26 CRDF Pocket Pivot Bullish Swing Setup
2021-02-26 CRDF Stochastic Buy Signal Bullish
2021-02-26 CRDF Lower Bollinger Band Walk Weakness
2021-02-26 FBIO 20 DMA Resistance Bearish
2021-02-26 GLYC Lower Bollinger Band Walk Weakness
2021-02-26 GMAB Lower Bollinger Band Walk Weakness
2021-02-26 KRON 20 DMA Support Bullish
2021-02-26 MBRX Stochastic Reached Oversold Weakness
2021-02-26 MRUS Lower Bollinger Band Walk Weakness
2021-02-26 MRUS Bullish Engulfing Bullish
2021-02-26 MRUS Crossed Above 50 DMA Bullish
2021-02-26 NEXI New 52 Week Closing High Bullish
2021-02-26 NK MACD Bearish Signal Line Cross Bearish
2021-02-26 NK Spinning Top Other
2021-02-26 SYRS Lower Bollinger Band Walk Weakness
2021-02-26 TRIL Lower Bollinger Band Walk Weakness
2021-02-26 TRIL 200 DMA Resistance Bearish
2021-02-26 XBIO Fell Below 50 DMA Bearish
2021-02-26 XBIO Stochastic Reached Oversold Weakness

Recent News for Acute Myeloid Leukemia Stocks

Date Stock Title
Feb 28 NK Cramer Advises Viewers On First Solar, Madison Square Garden Sports And More
Feb 27 GLYC The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
Feb 27 VOR The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
Feb 27 SYRS The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
Feb 27 FBIO The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
Feb 27 CRDF Could The Cardiff Oncology, Inc. (NASDAQ:CRDF) Ownership Structure Tell Us Something Useful?
Feb 26 GLYC GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences
Feb 26 GMAB Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Feb 26 GMAB Genmab A/S 2020 Q4 - Results - Earnings Call Presentation
Feb 26 FBIO Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
Feb 26 FBIO Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
Feb 26 NK SHAREHOLDER ALERT: Barr Law Group Investigating NK, IQDNX, JELD, and MDXG; Shareholders are Encouraged to Contact the Firm
Feb 25 CRDF Cardiff Oncology EPS misses by $0.05, beats on revenue
Feb 25 CLLS Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST
Feb 25 CRDF Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights
Feb 25 CRDF Cardiff Oncology: Can They Succeed Where Others Have Failed?
Feb 25 CTIC CTI BioPharma: Potential Light At End Of The Rainbow
Feb 25 SYRS Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 4, 2021
Feb 25 KRON Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
Feb 25 ARGX argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cells. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.Risk factors include smoking, previous chemotherapy or radiation therapy, myelodysplastic syndrome, and exposure to the chemical benzene. The underlying mechanism involves replacement of normal bone marrow with leukemia cells, which results in a drop in red blood cells, platelets, and normal white blood cells. Diagnosis is generally based on bone marrow aspiration and specific blood tests. AML has several subtypes; for which treatments and outcomes may vary.AML, typically is initially treated with chemotherapy aimed at inducing remission. People may then go on to receive additional chemotherapy, radiation therapy, or a stem cell transplant. The specific genetic mutations present within the cancer cells may guide therapy, as well as determine how long that person is likely to survive. Arsenic trioxide may be tried in cases that have recurred following usual treatments.AML affected about one million people globally in 2015 and resulted in 147,000 deaths. It most commonly occurs in older adults. Males are affected more often than females. AML is curable in about 35% of people under 60 years old and 10% over 60 years old. Older people who are not healthy enough to receive intensive chemotherapy have a typical survival of 5–10 months. It accounts for roughly 1.8% of cancer deaths in the United States.

More about Acute Myeloid Leukemia
Browse All Tags